ADORA2A and Parkinson disease: Not surprisingly, a number of selective adenosine A2A receptor antagonists have been developed [92] with the aim of increasing the duration of motor improvement seen during the time when symptoms are adequately controlled by medication (ON time) and decreasing the periods of inadequate control of PD symptoms (OFF time) in patients receiving levodopa but where insufficient efficacy is occurring [18,32,93].